# A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

> **NCT03312530** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 49 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Venetoclax
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03312530
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-13
- **Primary completion:** 2021-05-18
- **Final completion:** 2021-05-18
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312530, "A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03312530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*